Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지

Growth promoting effect of short-term gonadotropin releasing hormone agonist with or without growth hormone in girls with early puberty

조기 사춘기 여아에서 단기간 성선자극호르몬 방출호르몬 효능약제와 성장호르몬 병합투여의 성장촉진 효과

  • Lee, Eun-Ju (Department of Pediatrics, College of Medicine and Medical Research Institute, Chungbuk National University) ;
  • Han, Heon-Seok (Department of Pediatrics, College of Medicine and Medical Research Institute, Chungbuk National University)
  • 이은주 (충북대학교 의과대학 소아과학교실) ;
  • 한헌석 (충북대학교 의과대학 소아과학교실)
  • Received : 2006.09.05
  • Accepted : 2006.12.15
  • Published : 2007.02.15
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose : The hope that arresting pubertal developement might increase final adult height has led to an attempt to use GnRH agonist (GnRHa) in children with early puberty and poor growth prognosis. We investigated the growth-promoting effect of GnRH agonists with or without growth hormone (GH) in girls with early puberty and decreased predicted adult height (PAH). Methods : Thirty five girls with advanced bone age and early pubertal signs were randomized for treatment for about 1 year with monthly GnRHa in group 1 (n=18), or with a combination of GH and GnRHa in group 2 (n=17). The following growth parameters were compared between groups, and the difference ($\Delta$) before and after treatment : chronological age (CA), bone age (BA), $\Delta$(BA-CA), height (HT), target height (TH), predicted adult height (PAH), $\Delta$ (TH-PAH), serum insulin-like growth factor (IGF-1) and insulin-like growth factor binding protein (IGFBP-3). Results : Before treatment, BA, TH, PAH Standard deviation scores (SDS), $\Delta$(TH-PAH) were not different between the two groups, but CA was higher in group 2 and $\Delta$(BA-CA) were higher in group 1 (P<0.05). After $1.06{\pm}0.93$ year of treatment, $\Delta$ (BA-CA) decreased and there were significant changes in PAH and $\Delta$ (TH-PAH), especially in group 2 (P<0.05 in group 1, and P<0.001 in group 2). In both groups, IGF-1 and IGFBP-3 were not different before and after treatment, but after treatment, IGF-1 level in group 2 was marginally higher than IGF-1 in group 1 (P<0.1). Conclusion : Compromised predicted adult height in girls with early puberty and advanced bone age was significantly improved with GnRH with/without GH treatment in the short-term period. The addition of GH to GnRHa results in a significant increase in PAH compared to GnRHa alone because GnRHa suppressed growth hormone-IGF-1 axis. For comparison of final adult height, further longitudinal follow-up will be needed.

목 적: 성조숙증에서 관찰된 최근의 연구 결과를 보면 사춘기 발육이 빠른 당시에는 신장이 커보일 수 있으나 결국 최종성인신장은 감소하게 된다. 이에 사춘기를 중단시킴으로써 최종 성인신장을 증가시킬 수 있을 것이라는 기대로 성선자극호르몬 방출호르몬 효능약제를 사용하여 골성숙의 기간을 연장하고자 하였다. 또한 조기 사춘기로 인하여 최종성인신장의 예후가 불량한 소아에서 성선자극호르몬 방출호르몬 효능약제 및 성장호르몬의 병합요법 효과를 성선자극호르몬 방출호르몬 효능약제 단독 사용 시의 효과와 비교하여 각각의 성장 촉진 효과를 알아보고자 하였다. 방 법: 역연령에 비하여 골연령이 증가되어 있으며 조기 사춘기를 보이는 여아를 대상으로 GnRHa 및 성장호르몬을 단기간 투여하였다. 제 1군은 triptorelin을 단독으로 4주에 한 번씩 근육주사하였고, 제 2군은 성장호르몬을 병합하여 치료하였다. 치료 기간은 약 1년이었으며 치료 시작시와 치료 후의 두 군간의 역연령, 골연령, 역연령과 골연령의 차이, 예측성인신장, 표적키, 표적키와 예측성인신장과의 차이, 혈청 IGF-1 및 IGFBP-3치를 비교하였다. 결 과: 치료 시작시 두 군 간의 골연령, 표적키, 예측성인신장, 예측성인신장과 표적키의 차이는 없었으나 골연령과 역연령의 차이 및 역연령은 유의한 차이를 보였다. 혈청 IGF-1 및 IGFBP-3값의 차이는 없었고 평균 치료기간은 $1.06{\pm}0.93$년이었다. 치료 후의 골연령과 역연령의 차이는 전체적으로 감소하였으며 두 군간에도 유의한 차이를 보였다. 치료 후의 예측성인신장은 치료전과 비교했을 때 모두 증가하여 단기간의 치료에도 효과가 있었으며 두 군 모두 의미 있는 값을 가지나 특히 성장호르몬을 같이 사용한 2군에서 더욱 큰 차이를 보여 병합요법의 성장촉진효과를 알 수 있었다. 표적키와 예측성인신장의 차이는 전체적으로 치료전보다 의미 있는 감소를 보였으며 두 군을 비교했을때 역시 2군에서 더욱 의미 있게 감소하였다. 혈청 IGF-1과 IGFBP-3는 GnRHa 사용 후에 성장호르몬-IGF 축이 억제되어 1군에서 모두 감소하였으나 성장호르몬을 병합한 2군에서는 모두 증가하였고 이때 통계적인 의미는 없었다. 결 론: 조기 사춘기로 인하여 역연령에 비해 골연령이 증가함으로써 성인신장에 나쁜 영향을 끼치는 경우에는 단기간의 GnRHa의 사용으로 사춘기의 빠른 진행을 억제하고 골성숙의 기간을 연장시킴으로써 예측성인신장을 증가시킬 수 있다. 또한 성장호르몬 병합요법으로 예측성인신장이 표적키에 도달하는데 있어 GnRHa 만으로 성장호르몬-IGF 축이 억제된 경우보다 성장촉진 효과를 나타낸다. 그러나 이는 단기간 사용 시의 치료효과이므로 최종성인신장의 비교를 위해서는 향후 장기적인 추적관찰이 필요하다.

Keywords

Acknowledgement

Supported by : 충북대학교

References

  1. Kaplan SL, Grumbach MM. Clinical review 14: Pathophysiology and treatment of sexual precocity. J Clin Endocrinol Metab 1990;71:785-9 https://doi.org/10.1210/jcem-71-4-785
  2. Bath LE, Brown DC, Kelnar CJH. Precocious puberty. Current Paediatr 1999;9:242-6 https://doi.org/10.1054/cupe.1999.0061
  3. Rosenfield RL. Selection of children with precocious puberty for treatment with gonadotropin releasing hormone analogs. J Pediatr 1994;124:989-91 https://doi.org/10.1016/S0022-3476(05)83200-7
  4. Saggese G, Pasquino AM, Bertelloni S, Baroncelli GI, Battini R, Pucarelli I, et al. Effects of combined treatment with gonadotropin releasing hormone analogue and growth hormone in patients with central precocious puberty who had subnormal growth velocity and impaired height prognosis. Acta Paediatr 1995;84:299-304 https://doi.org/10.1111/j.1651-2227.1995.tb13632.x
  5. Pucarelli I, Segni M, Ortore M, Moretti A, Iannaccone R, Pasquino AM. Combined therapy with GnRH analog plus growth hormone in central precocious puberty. J Pediatr Endocrinol Metab 2000;13:811-20
  6. Greulich WW, Pyle SI. Radiographic atlas of skeletal development of the hand and wrist. 2nd ed. Standford. California: Standford univ. press 1993
  7. Bayley N, Pimenan SR. Tables for predicting adult height from skeletal age: revised for use with the Greulich-Pyle hand standards. J Pediatr 1952;40:423-41 https://doi.org/10.1016/S0022-3476(52)80205-7
  8. Garibaldi L. Disorders of pubertal development. In: Behrman R, Kliegman R, Jenson H. editors. Nelson Textbook of Pediatrics, 17th ed. Philadelphia: Saunders, 2004:1863-70
  9. Parent AS, Teilmann G, Juul A, Niels E, Skakkebaek, Toppari J, et al. The timing of normal puberty and the age limits of sexual precocity: Variation around the world, secular trend and changes after migration. Endocr Rev 2003;24:668-93 https://doi.org/10.1210/er.2002-0019
  10. Kreiter M, Burstein S, Rosenfield RL, Moll GW Jr, Cara JF, Yousefzadeh DK, et al. Preserving adult height potential in girls with idiopathic true precocious puberty. J Pediatr 1990;117:364-70 https://doi.org/10.1016/S0022-3476(05)81074-1
  11. Lazar L, Pertzelan A, Weintrob N, Phillip M, Kauli R. Sexual precocity in boys: accelerated versus slowly progressive puberty gonadotropin-suppressive therapy and final height. J Clin Endocrinol Metab 2001;86:4127-32 https://doi.org/10.1210/jc.86.9.4127
  12. Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Arch Dis Child 1969;44:291-303 https://doi.org/10.1136/adc.44.235.291
  13. Marshall WA, Tanner JM. Variations in the pattern of pubertal changes in boys. Arch Dis Child 1970;45:13-23 https://doi.org/10.1136/adc.45.239.13
  14. Antoniazzi F, Zamboni G. Central precocious puberty: current treatment options. Paediatr Drugs 2004;6:211-31 https://doi.org/10.2165/00148581-200406040-00002
  15. Kaplowitz PB, Overfield SE. Reexamination of the age limit for defining when puberty is precocious in girls in the United States: implications for evaluation and treatment. pediatrics 1999;104:936-41 https://doi.org/10.1542/peds.104.4.936
  16. Fredriks AM, van Buuren S, Burgmeijer RJ, Meulmeester JF, Beuker RJ, Brugman E, et al. Continuing positive secular growth change in the Netherlands 1955-1997. Pediatr Res 2000;47:316-23 https://doi.org/10.1203/00006450-200003000-00006
  17. de Muinich Keizer SM, Mul D. Trends in pubertal development in Europe. Hum Reprod Update 2001;7:287-91 https://doi.org/10.1093/humupd/7.3.287
  18. Iughetti L, Predieri B, Ferrari M, Gallo C, Livio L, Milioli S, et al. Diagnosis of central precocious puberty: Endocrine assessment. J Pediatr Endocrinol Metab 2000;13:709-15
  19. Partsch CJ, Heger S, Sippell WG. Management and outcome of central precocious puberty. Clin Endocrinol 2002;56:129-48 https://doi.org/10.1046/j.0300-0664.2001.01490.x
  20. Haber HP, Wollmann HA, Ranke MB. Pelvic ultrasonography: early differentiation between isolated premature thelarche and central precocious puberty. Eur J Pediatr 1995;154:182-6 https://doi.org/10.1007/BF01954267
  21. Sonis WA, Comite F, Blue J, Prescovitz OH, Rahn CW, Hench KD, et al. Behavior problems and social competence in girls with true precocious puberty. J Pediatr 1985;106: 156-60 https://doi.org/10.1016/S0022-3476(85)80489-3
  22. Schoevaart CE, Drop SL, Otten BJ, Slijper FM, Degenhart HJ. Growth analysis up to final height and psychosocial adjustment of treated and untreated patients with precocious puberty. Horm Res 1990;34:197-203 https://doi.org/10.1159/000181825
  23. Antoniazzi F, Cisternino M, Nizzoli G, Bozzola M, Corrias A, De Luca F, et al. Final height in girls with central precocious puberty: comparison of two different luteinizing hormone- releasing hormone agonist treatments. Acta Paediatr 1994;83:1052-6 https://doi.org/10.1111/j.1651-2227.1994.tb12984.x
  24. Roger M, Chaussain JL, Berlier P, Bost M, Canlorbe P, Colle M, et al. Long term treatment of male and female precocious puberty by periodic administration of a long-acting preparation of D-Trp6-luteinizing hormone-releasing hormone microcapsules. J Clin Endocrinol Metab 1986;62:670-7 https://doi.org/10.1210/jcem-62-4-670
  25. Carel JC, Roger M, Ispas S, Tondu F, Lahlou N, Blumberg J, et al. Final height after long-term treatment with triptorelin slow release for central precocious puberty: importance of statural growth after interruption of treatment. French study group of Decapeptyl in precocious puberty. J Clin Endocrinol Metab 1999;84:1973-8 https://doi.org/10.1210/jc.84.6.1973
  26. Harris DA, Van Vliet G, Egli CA, Grumbach MM, Kaplan SL, Styne DM, et al. Somatomedin-C in normal puberty and in true precocious puberty before and after treatment with a potent luteinizing hormone-releasing hormone agonist. J Clin Endocrinol Metab 1985;61:152
  27. DiMartino-Nardi J, Richard WU, Fishman, Saenger K. The effect of long-acting analog of luteinizing hormone-releasing hormone on growth hormone secretory dynamics in children with precocious puberty. J Clin Endocrinol Metab 1991;73: 902-6 https://doi.org/10.1210/jcem-73-4-902
  28. Juul A, Scheike T, Nielsen CT, Krabbe S, Muller J, Skakkeba NE. Serum insulin-like growth factor I(IGF-1) and IGF-binding protein 3 levels are increased in central precocious puberty: Effects of two different treatment regimens with gonadotropin releasing hormone agonist, without or in combination with an antiandrogen. J Clin Endocrinol Metab 1995;80:3059-67 https://doi.org/10.1210/jc.80.10.3059
  29. Galluzzi F, Salti R, Bindi G, Pasquini E, La Cauza C. Adult height comparison between boys and girls with precocious puberty after long-term gonadotropin releasing hormone analogue therapy. Acta Paediatr 1998;87:521-7 https://doi.org/10.1080/08035259850158227
  30. Sklar CA, Rothenberg S, Bumberg D, Oberfield SE, Levine LS, David R. Suppression of the pituitary-gonadal axis in children with central precocious puberty; effects on growth, growth hormone, insulin-like growth factor-1, and prolactin secretion. J Clin Endocrinol Metab 1991;73:734-8 https://doi.org/10.1210/jcem-73-4-734
  31. Klein KO, Klein O, Barnes KM, Jones JV, Feuillan PP, Cutler GB. Increased final height in precocious puberty after longterm treatment with LHRH agonists: The national institutes of health experience. J Clin Endocrinol Metab 2001;86:4711-6 https://doi.org/10.1210/jc.86.10.4711
  32. Mul D, Oostdijk W, Waelkens JJ, Schulpen TW, Drop SL. Gonadotrophin releasing hormone agonist treatment with or without recombinant human GH in adopted children with early puberty. J Clin Endocrinol 2001;55:121-93 https://doi.org/10.1046/j.1365-2265.2001.01315.x
  33. Tuvemo T, Jonsson B, Gustafsson J, Albertsson-Wikland K, Aronson AS, Hager A, et al. Final height after combined growth hormone and GnRH analogue treatment in adopted girls with early puberty. Acta Paediatr 2004;93:1456-62 https://doi.org/10.1080/08035250410021793
  34. Tato L, Saggese G, Cavallo L, Antoniazzi F, Corrias A, Pasquino AM, et al. Use of combined GnRH agonist and hGH therapy for better attaining the goals in precocious puberty treatment. Horm Res 1995;44 Suppl 3:49-54 https://doi.org/10.1159/000184674
  35. Antoniazzi F, Bertoldo F, Lauriola S, Sirpresi S, Gasperi E, Zamboni G, et al. Prevention of bone demineralization by calcium supplementation in precocious puberty during gonadotropin- releasing hormone agonist treatment. J Clin Endocrinol Metab 1999;84:1992-6 https://doi.org/10.1210/jc.84.6.1992
  36. Heger S, Partsch CJ, Sippell WG. Long-term outcome after depot gonadotropin-releasing hormone agonist treatment of central precocious puberty: final height, body proportions, body composition, bone mineral density, and reproductive function. J Clin Endocrinol Metab 1999;84:4583-90 https://doi.org/10.1210/jc.84.12.4583